Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Ralliant's Fiscal Q3 Adjusted Earnings, Revenue Increase; Fiscal 2026 Outlook Raised

Ralliant's Fiscal Q3 Adjusted Earnings, Revenue Increase; Fiscal 2026 Outlook Raised

MT newswireMT newswire2026/11/04 10:54
06:54 AM EST, 11/04/2026 (MT Newswires) -- Ralliant (RAL) reported fiscal Q3 adjusted earnings Wednesday of $0.93 per diluted share, up from $0.60 a year earlier. Analysts polled by FactSet expected $0.77. Sales for the quarter ended Oct. 2 were $620.1 million, compared with $529.1 million a year earlier. Analysts expected $586 million. The company expects fiscal Q4 adjusted EPS of $0.93 to $0.99 on revenue of $620 million to $640 million. Analysts expect $0.85 in adjusted EPS on revenue of $609 million. For fiscal 2026, Ralliant raised its outlook to adjusted EPS of $3.10 to $3.16 on revenue of $2.34 billion to $2.36 billion. The company previously projected adjusted EPS of $2.76 to $2.90 and $2.25 billion to $2.30 billion in revenue. Analysts expect adjusted EPS of $2.87 and $2.30 billion in revenue. Shares of Ralliant were up more than 8% in recent Wednesday premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss